Glycopyrrolate/formoterol fumarate vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Reported efficacy
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)
Result source: NCT02184611
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrrolate/formoterol fumarate | Umeclidinium |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Trial running · NCT06474039 |
| Trough FEV1, change | —Not reported | 0.1 vs -0.0+0.2 vs placeboNCT0218461121 other results
|
| SGRQ total, change | —Not reported | -6.2 vs -2.1−4 vs placeboNCT021526055 other results
|
| TDI focal score | —Not reported | 2.5 vs 1.6+0.9 vs placeboNCT02184611 |
Moderate or severe exacerbations, annualised rate
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium
- —Trial running · NCT06474039
Trough FEV1, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium
- 0.1 vs -0.0+0.2 vs placeboNCT02184611
21 other results
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT02119286
- 0.1 vs -0.0 NCT02119286
- 0.2 vs 0.1 NCT02207829
- 0.2 vs 0.2 NCT02257385
- 0.1 vs 0.1 NCT02729051
- 0.2 vs 0.0 NCT02152605
- 0.2 vs 0.1 NCT01879410
- 0.1 vs -0.0 NCT02257372
- 0.1 vs -0.0 NCT03034915
- 0.1 vs 0.1 NCT02236611
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.2 vs -0.0 NCT02275052
SGRQ total, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium
- -6.2 vs -2.1−4 vs placeboNCT02152605
5 other results
- -7.3 vs -4.3 NCT02184611
- -7.0 vs -2.5 NCT02184611
- -5.8 vs -1.4 NCT02184611
- -5.8 vs -4.9 NCT02729051
- -5.0 vs -3.3 NCT03034915
TDI focal score
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium
- 2.5 vs 1.6+0.9 vs placeboNCT02184611
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Glycopyrrolate/formoterol fumarate: 3 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrrolate/formoterol fumarate | Umeclidinium |
|---|---|---|
| Exercise Endurance Time Seconds absolute value · seconds | 382.5 vs 328 placebo secondsa,b,c NCT03081156 · Phase 4 · registry result, not featured evidence | -2.06 vs -5.37 placebo seconds @ 12wk62.5/25 mcga,b,c NCT02275052 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 0%d NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | 13.7%62.5 mcge NCT02184611 · Phase 3 show 25 more results8.9%125 µg QD NCT01772147 · Phase 3 · combination 12.3%62.5 µg QD NCT01772147 · Phase 3 · combination 5.3%62.5 µg NCT01957163 · Phase 3 · combination 8.7%125 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT02119286 · Phase 3 · combination 5.3%62.5 µg NCT02119286 · Phase 3 · combination 10.7%125 µg QD NCT01772134 · Phase 3 · combination 6.9%62.5 µg QD NCT01772134 · Phase 3 · combination 11.7%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 5%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 8.4%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 8.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.6%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 7.3%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —d NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | 2.4%62.5 mcge NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 4.9%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 1.9%125 µg NCT01957163 · Phase 3 · combination 1%125 µg NCT02119286 · Phase 3 · combination 3.4%62.5 µg NCT02119286 · Phase 3 · combination 4.9%125 µg QD NCT01772134 · Phase 3 · combination 2.5%62.5 µg QD NCT01772134 · Phase 3 · combination 3.6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 1.9%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5.9%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 2%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 2.5%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 0%d NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence | 8.3%62.5 mcge NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 3%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT01957163 · Phase 3 · combination 1.4%125 µg NCT02119286 · Phase 3 · combination 3.9%62.5 µg NCT02119286 · Phase 3 · combination 2.9%125 µg QD NCT01772134 · Phase 3 · combination 2%62.5 µg QD NCT01772134 · Phase 3 · combination 6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence 3%62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.4%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence 6.9%62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence 1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | — | 62.5 mcge upper respiratory tract infection 12.2% (placebo 12.9%) nasopharyngitis 9.3% (placebo 10.9%) dizziness 2.9% (placebo 2%) NCT02184611 · Phase 3 show 23 more results125 µg QD nasopharyngitis 5% (placebo 4.5%) headache 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.5%) nasopharyngitis 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg headache 4.4% (placebo 2.9%) back pain 3.4% (placebo 1.5%) nasopharyngitis 3.4% (placebo 3.4%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 4.8% (placebo 3.4%) headache 4.3% (placebo 2.9%) cough 3.4% (placebo 0.5%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 9.2% (placebo 10.7%) headache 1.9% (placebo 2.4%) back pain 1% (placebo 1.9%) NCT02119286 · Phase 3 · combination 62.5 µg nasopharyngitis 5.3% (placebo 10.7%) back pain 3.9% (placebo 1.9%) headache 3.9% (placebo 2.4%) NCT02119286 · Phase 3 · combination 125 µg QD headache 6.3% (placebo 4.9%) cough 2.4% (placebo 1.5%) nasopharyngitis 2.4% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.9%) cough 3.4% (placebo 1.5%) nasopharyngitis 2.5% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 mcg QD headache 8.1% nasopharyngitis 8.1% NCT02236611 · Phase 4 · registry result, not featured evidence 62.5 mcg+ICS/LABA nasopharyngitis 13.4% (placebo 14.5%) headache 3.4% (placebo 6.8%) cough 2.5% (placebo 4.3%) NCT02257372 · Phase 4 · registry result, not featured evidence · combination 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence 62.5 mcg QD headache 5.9% nasopharyngitis 5.3% NCT02207829 · Phase 3 · registry result, not featured evidence 62.5/25 µg headache 7.5% nasopharyngitis 6.6% cough 3.3% NCT02257385 · Phase 3 · registry result, not featured evidence 62.5/25mcg headache 6.5% (placebo 6.5%) nasopharyngitis 5.2% (placebo 6.5%) NCT02152605 · Phase 3 · registry result, not featured evidence 62.5/25 mcg headache 6.9% nasopharyngitis 4% NCT01879410 · Phase 3 · registry result, not featured evidence 62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for 1 of these studies.
- ePopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrrolate/formoterol fumarate
Umeclidinium
show 21 more results
show 10 more results
show 5 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 4 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Umeclidinium's landscape